Kymera Therapeutics, Inc. entered into an underwriting agreement to issue and sell shares of its common stock and pre-funded warrants, with estimated net proceeds of $301.1 million, to advance its pipeline and for general corporate purposes.
AI Assistant
KYMERA THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.